Bio-Rad Laboratories, Inc.

NYSE:BIO

Medical - Devices

Healthcare
$370.17 -0.23%

-$0.65 today

Market cap
$9.95B
Beta
1.08
P/E (TTM)
45.4
EPS (TTM)
$6.26
52W Low $228.40High $343.12

Volume 0.46M

Average 0.38M

BIO Long-term Debt

Borrowings due after more than one year.

Bio-Rad Laboratories, Inc.NYSE: BIO

Long-term Debt · Q2 FY2026 · quarter ended Jun 2026

Long-term debt falls 33.1% from a year ago

Long-term debt stood at $803M at the end of Q2 FY2026, down 33.1% from a year earlier and up 1.1% from the prior quarter. Over 3 fiscal years it compounded at +3.8% a year.

Context

  • Long-term debt amounted to 7.8% of total assets at the end of Q2 FY2026, down 3.9 pp from a year earlier.
  • Long-term debt increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term debt keeps falling in the next quarterly balance sheet after a -33.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$803M+1.1% QoQ
Last fiscal yearDec 2025
$1.34B+11.5% YoY
Year agoJun 2025
$1.2B-33.1% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33.1%——
1 year+11.5%——
3-year CAGR+3.8%——
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
1.34B USD
Year-over-year change
+11.5%
4-year CAGR
+235.9%

Long-term Debt vs competitors

How BIO compares with its peers on the latest reported figures

  • BIO's Jun 2026 long-term debt of $803M is the 5th highest of the 11 companies compared; the peer median is $597.58M.
  • Its year-over-year change of -33.1% is the 8th highest of 10, against a peer median of -0.3%.
  • Long-term debt amounts to 7.8% of total assets for BIO, versus a peer median of 23.0%.
BIO Competitors Peer median
Long-term Debt for BIO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TMOThermo Fisher Scientific Inc.Sep 2026$39.11B +22.8%+7.4%34.2%
DHRDanaher CorporationSep 2026$24.39B +44.9%-1.2%26.1%
RVTYRevvity, Inc.Jul 2026$2.63B -18.1%-10.9%21.9%
BRKRBruker CorporationJun 2026$1.81B -23.7%+12.2%30.0%
BIOBio-Rad Laboratories, Inc.Jun 2026$803M -33.1%+3.8%7.8%
PACBPacific Biosciences of California, Inc.Mar 2026$644.11M -0.3%-7.8%82.3%
RGENRepligen CorporationJun 2026$551.05M +3.2%—18.7%
MRVIMaravai LifeSciences Holdings, Inc.Jun 2026$145.98M -49.4%-61.3%24.2%
LABStandard BioTools Inc.Mar 2026$299K +0.0%-83.2%0.0%
TECHBio-Techne CorporationSep 2026$0 -100.0%-17.0%0.0%
AZTAAzenta, Inc.Sep 2026$0 ——0.0%
Peer median (excluding BIO) $597.58M-0.3%-9.3%23.0%

Competitors are the stored peer set for BIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents470.78M434.22M403.8M488.1M531.8M
Short-term Investments399.14M1.36B1.2B1.18B1.01B
Net Receivables423.54M494.65M489M452.5M472.5M
Inventory572.24M719.32M780.5M760M740.7M
Other Current Assets15.65M29.16M31.7M30.7M13.8M
Total Current Assets1.99B3.16B3.05B3.03B2.91B
Property, Plant & Equipment (Net)716.44M679.55M723.7M688.6M709.9M
Goodwill347.3M406.5M413.6M410.5M579.8M
Intangible Assets253.9M332.1M320.5M293.6M174.3M
Long-term Investments14.39B8.83B7.7B4.84B6.1B
Tax Assets00000
Other Non-current Assets104.19M94.6M94.9M101.9M102.3M
Total Non-current Assets15.81B10.34B9.25B6.33B7.67B
Total Assets17.8B13.5B12.3B9.36B10.58B
Account Payables141.94M135.04M144.6M122.3M129M
Short-term Debt489K465K500K1.2M37.9M
Tax Payables46.3M32.43M35.8M31.2M36.6M
Deferred Revenue50.85M52.21M000
Other Current Liabilities127.94M117.44M161.6M147.2M141.2M
Total Current Liabilities680.94M568.71M522.8M467.8M517M
Long-term Debt10.51M1.2B1.2B1.2B1.34B
Deferred Tax Liabilities3.06B1.77B1.48B818M1.06B
Deferred Revenue (Non-current)00000
Other Non-current Liabilities182.19M195.93M195M177.2M53.4M
Total Non-current Liabilities3.43B3.32B3.04B2.33B2.61B
Total Liabilities4.11B3.89B3.56B2.79B3.12B
Common Stock3K3K000
Retained Earnings13.53B9.9B9.26B7.42B8.18B
Accumulated OCI(175.55M)(466.82M)(336M)(538.2M)(189.1M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity13.69B9.62B8.74B6.57B7.45B
Total Debt223.38M1.39B1.41B1.37B1.53B
Net Debt(247.41M)953.88M1B886.6M999.2M

Bio-Rad Laboratories, Inc.

NYSE:BIO

Intrinsic Alpha fair value

Locked

Current Price

$370.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.